High-Throughput Gene Expression and Mutation Profiling: Current Methods and Future Perspectives
暂无分享,去创建一个
[1] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[2] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[3] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[4] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[6] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[7] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[8] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[9] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[10] P. Neven,et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[12] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[13] D. Steensma. The beginning of the end of the beginning in cancer genomics. , 2013, The New England journal of medicine.
[14] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Achim Rody,et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.
[16] I. Ellis,et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.
[17] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[18] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[19] A. Zlotta. Words of wisdom: Re: Genome sequencing identifies a basis for everolimus sensitivity. , 2013, European urology.
[20] P. Campbell,et al. Next-generation sequencing in breast cancer: first take home messages , 2012, Current opinion in oncology.
[21] Lucia A. Hindorff,et al. Genetic architecture of cancer and other complex diseases: lessons learned and future directions. , 2011, Carcinogenesis.
[22] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[23] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[24] John P A Ioannidis,et al. Improving Validation Practices in “Omics” Research , 2011, Science.
[25] Yuan Qi,et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[27] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[28] Joe Gray,et al. Genomics: The breast cancer landscape , 2012, Nature.
[29] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[30] Martin A. Nowak,et al. Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.
[31] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[32] C. Corless. Personalized Cancer Diagnostics , 2011, Science.
[33] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[34] D. Shibata. Heterogeneity and Tumor History , 2012, Science.
[35] Charles M. Perou,et al. Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.
[36] Christine Solbach,et al. Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.
[37] T. Karn,et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. , 2007, Breast.
[38] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[39] Carlos Caldas,et al. A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.
[40] Carlos Caldas,et al. The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.
[41] Francisco M. De La Vega,et al. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.
[42] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[43] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[44] H. Ohtsuki,et al. Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.
[45] M. Guyer,et al. Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.
[46] Stephen J. Chanock,et al. Current status of genome-wide association studies in cancer , 2011, Human Genetics.
[47] Lajos Pusztai,et al. A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.
[48] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[49] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[50] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[51] T. Dallman,et al. Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.
[52] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[53] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[55] H. Kölbl,et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.
[56] L. Pusztai,et al. Use of standard markers and incorporation of molecular markers into breast cancer therapy , 2011, Cancer.
[57] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[58] E. Lander,et al. Lessons from the Cancer Genome , 2013, Cell.
[59] Charles Swanton,et al. Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.
[60] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[61] L. Pusztai,et al. Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.